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Available online 25 March 2008Cyclophilin A (CypA) is a peptidyl-prolyl isomerase that binds to the capsid protein of human immunodeﬁciency
virus type 1 (HIV-1). TRIM5α is an antiretroviral factor inﬂuencing species-speciﬁc retroviral replication in Old
Worldmonkey (OWM) cells. In the study reported here, we investigated the role of CypA in anti-HIV-1 activity of
OWM cells. Exogenous expression of CypA inhibited HIV-1 infection in OWM cells but not in human cells when
the function of TRIM5α was suppressed by overexpression of dominant negative form of TRIM5α as well as by
using RNA interference. This inhibitory action depended upon the interaction of the CypA moiety with HIV-1
capsid and disruption of CypA and capsid interaction by cyclosporine A enhanced the HIV-1 susceptibility of
OWM cells even in the absence of functional TRIM5α. These results point to the presence of novel TRIM5α-
independent anti-HIV-1 activity mediated by CypA in OWM cells.
© 2008 Elsevier Inc. All rights reserved.Keywords:
Cyclophilin A
TRIM5
HIV-1
Old World monkeyIntroduction
The hydrophobic pocket of cyclophilin A (CypA) makes direct
contact with the proline residue at the 90th position and adjacent
residues on the surface-exposed loop between α-helices 4 and 5 (the
h4/5 loop) of human immunodeﬁciency virus type 1 (HIV-1) capsid
(CA) (Franke et al., 1994; Gamble et al., 1996; Luban et al., 1993). This
interaction can be disrupted experimentally by mutations that alter
CA proline 90 or adjacent residues (Franke et al., 1994), by competitive
inhibitors of the interaction including cyclosporine A (CsA) (Braaten et
al., 1996a; Franke and Luban, 1996; Thali et al., 1994), by CypA
knockout by means of gene targeting (Braaten and Luban, 2001), or by
CypA knock-down with RNA interference (RNAi) (Sokolskaja et al.,
2006; Sokolskaja et al., 2004). Each of these interventions reduces
HIV-1 susceptibility in human cells (Braaten et al., 1996a; Braaten and
Luban, 2001; Franke and Luban, 1996; Franke et al., 1994; Rosenwirth
et al., 1994; Sokolskaja et al., 2006, 2004), with the block occurring
early, at the time of reverse transcription (Braaten et al., 1996b).
Recent data have led to the hypothesis that, by binding to CA, CypA
protects HIV-1 against antiviral restriction activity in human cells
(Luban, 2007; Towers, 2007).
In contrast with the situation in human cells, HIV-1 replication in
cells from several Old World monkeys (OWM) encounters a block
before completion of reverse transcription due to their tripartite motif
(TRIM) 5α (Stremlau et al., 2004). TRIM5α is a member of the tripartite
motif protein family, which comprises RING, B-box and a coiled-coil
domains (Reymond et al., 2001). Rhesus (Rh) and cynomolgusmonkeyayama).
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NM) TRIM5αs inhibit HIV-1 but not simian immunodeﬁciency virus
om macaque (SIVmac), whereas African green monkey (AGM)
RIM5α prevents replication of both HIV-1 and SIVmac (Hatziioannou
t al., 2004; Keckesova et al., 2004; Nakayama et al., 2005; Stremlau et
l., 2004). Human (Hu) TRIM5α shows very weak antiviral activity
gainst those viruses (Perez-Caballero et al., 2005; Sawyer et al., 2005;
tremlau et al., 2004, 2005; Yap et al., 2005) but confers strong
esistance against N-tropic murine leukemia virus (N-MLV) (Hat-
iioannou et al., 2004; Perron et al., 2004; Yap et al., 2004). Among
everal splicing variants of TRIM5, an α isoform carries the SPRY or
30.2 domain that determines virus speciﬁcity of this intracellular
ctor (Nakayama et al., 2005; Perez-Caballero et al., 2005; Sawyer et
l., 2005; Stremlau et al., 2004, 2005; Yap et al., 2005).
CsA treatment has been reported to increase HIV-1 replication in
WM cell lines (Berthoux et al., 2004; Kootstra et al., 2003; Towers et
l., 2003). Recently, two groups investigated the role of CypA in OWM
RIM5α antiviral activity and suggested that CypA acts in trans to
romote TRIM5α-mediated restriction of HIV-1 (Berthoux et al., 2005;
eckesova et al., 2006). Berthoux et al. reported that HIV-1 suscept-
ility increased in response to CypA knock-down to the same extent
s observed in response to TRIM5 knock-down by RNAi in Rh FRhK4
ells. However, simultaneous knock-down of both CypA and TRIM5
aused minimal additional increase, suggesting that CypA inhibits
IV-1 replication in Rh cells in a TRIM5α-dependent manner. These
ndings suggest that CypA is required for efﬁcient CA recognition by
RIM5α (Berthoux et al., 2005). Keckesova et al. (2006) also failed to
bserve additional increase in HIV-1 susceptibility in TRIM5α-
nocked-down AGM and Rh cells in response to CsA treatment.
either of these reports, however, used the overexpression system of
CypA protein.
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possess CypA as a fusion protein with TRIM5 (TRIMCyp) (Nisole et al.,
2004; Sayah et al., 2004). In a mutagenesis study of TRIMCyp, deletion
of the RING domain of TRIMCyp only partially reduced the ability of
the TRIMCyp protein to restrict HIV-1, suggesting that overexpression
of CypA-like proteins can results in a diminished susceptibility of cells
to HIV-1 (Diaz-Griffero et al., 2006). These ﬁndings prompted us to
test the effect of exogenous expression of CypA in OWM cells,
especially in the absence of functional TRIM5α and we were able to
show that CypA suppresses HIV-1 infection in OWM cells even in the
absence of functional TRIM5α.
Results
Exogenous expression of CypA reduces HIV-1 susceptibility in OWM cells
in TRIM5α-independent manner
To examine the effect of exogenously expressed CypA on HIV-1
infectivity in OWM cells, Sendai virus (SeV) vector systemwas used to
express CypA. HIV-1 susceptibility was then tested by using vesicular
stomatitis virus G (VSV-G) protein-pseudotyped HIV-1 vector encod-
ing green ﬂuorescence protein (GFP). AGM-TRIM5-speciﬁc siRNA
transfection was used to reduce TRIM5 levels. Real time PCR analysis
revealed that TRIM5 mRNA levels in siRNA transfected cells were
reduced to 23.6% of those of control siRNA transfected cells. As shown
in Fig.1, the TRIM5-speciﬁc siRNA transfection greatly enhanced HIV-1
susceptibility in AGM CV1 cells, suggesting the critical role of TRIM5α
to restrict HIV-1 in CV1 cells. Exogenous expression of CypA
apparently reduced HIV-1 infectivity in the absence of TRIM5α
expression, suggesting that CypA may restrict HIV-1 in OWM cells in
a TRIM5α-independent manner. On the other hand, CypA expression
showed no additive effect on HIV-1 restriction in the presence of
TRIM5α. This indicates that the amount of endogenous CypA in the
presence of TRIM5α in CV1 cells is sufﬁcient to restrict HIV-1.
Since there is one concern that the residual TRIM5α after siRNA
knock-down might interact with exogenous CypA, we used SeV
expressing CM TRIM5α lacking the SPRY domain (CM-SPRY(-)-SeV) to
eliminate function of endogenous TRIM5α. It was reported previously
that TRIM5 splicing variant TRIM5γ, which lacks SPRY domain,
dominantly interfered with the antiviral activity of TRIM5α (StremlauFig. 1. CV1 cells were transfected with siRNA against AGM TRIM5 (triangles) or
SiCONTROL Non-targeting siRNA#2 as a negative control (circles). Two days after
transfection, cells were infected with SeV expressing CypA (black triangles or black
circles) or empty SeV vector parental Z strain (white triangles and white circles) at a
multiplicity of infection (MOI) of 10 plaque forming units (PFUs) per cell and incubated
at 37 °C for 16 h. Serially diluted VSV-pseudotyped HIV-1 vectors encoding GFP were
inoculated, and infected cells were counted with a ﬂowcytometer.et al., 2004). CM-SPRY(-)-SeV had been shown to efﬁciently interfere
with HIV-1 suppression mediated by over-expressed CM, AGM, Rh
and human TRIM5αs (Maegawa et al. submitted). In addition, CM-
SPRY(-)-SeV was able to introduce dominant negative TRIM5 mutant
to virtually all the cells in a dish, and was also able to suppress anti-
HIV-1 activity of TRIM5a much more efﬁciently than siRNA
(Maegawa et al. unpublished result). Effects of CM-SPRY(-)-SeV on
HIV-1 infection was not observed in human cells (Fig. 2), conﬁrming
that SPRY(-) mutant TRIM5 speciﬁcally interfere with TRIM5α
function. SeV expressing AGM TRIM5α lacking the coiled-coil region
(AGM-CC(-)-SeV), was used as a non-interfering control. AGM cell
lines Vero and CV1, Rh cell line LLC-MK2 and human cell lines 293T
and MT4, were tested for their HIV-1 susceptibility in the presence of
exogenous CypA. We also constructed SeV expressing CypA, which
carries an HA tag (YPYDVPDYAA) at its C-termini (CypA-HA). Cells
were ﬁrst infected with AGM-CC(-)-SeV or CM-SPRY(-)-SeV, mixed
with a SeV expressing CypA or CypA-HA, or with an empty SeV
vector parental Z strain, incubated at 37 °C for 16 h, and then
challenged with VSV-G-pseudotyped HIV-1 vector encoding GFP.
Consistent with our previous ﬁnding, CM-SPRY(-)-SeV infection
enhanced HIV-1 susceptibility in OWM cells but not in human cells
(Fig. 2). As shown in Figs. 2B, D, and F, exogenous expression of CypA
in OWM cells dramatically reduced HIV-1 susceptibility when
endogenous TRIM5α were interfered with overexpression of the
dominant negative form of TRIM5α. In contrast, the exogenous
expression of CypA showed only a slight additional enhancement of
HIV-1 susceptibility in the presence of endogenous TRIM5α (Figs. 2A,
C, E). The exogenous expression of the HA-tagged version of CypA
had a similar suppressive effect on HIV-1 infection, even though the
effect was slightly weaker than that of the non-tagged version of
CypA (Figs. 2B, D, and F). These results are consistent with the
ﬁndings from the siRNA experiment shown in Fig. 1. In contrast to
OWM cell lines, human cell lines were not affected by the exogenous
expression of CypA or CypA-HA in HIV-1 susceptibility either in the
presence or absence of functional endogenous TRIM5α (Figs. 2G to J).
Similar results were observed when we used the empty SeV vector in
stead of AGM-CC(-)-SeV (data not shown). We clearly detected
expression of exogenous CypA-HA as well as those of endogenous
CypA in human and OWM cell lines, although the levels of expression
of exogenous CypA were slightly low in human cells than in OWM
cells (Fig. 2K). Taken together, these results indicate that the
exogenous expression of CypA in OWM cells has a potent antiviral
activity in TRIM5α-independent manner.
Endogenous CypA also restricts HIV-1 infection in OWM cells in TRIM5α
independent manner
CsA treatment disrupts the interaction between CypA and viral
capsid and has been reported to increase HIV-1 replication in OWM
cells and reduce that in human cells (Berthoux et al., 2004, 2005;
Keckesova et al., 2006; Kootstra et al., 2003; Stremlau et al., 2006;
Towers et al., 2003). We treated AGM-CC(-)-SeV or CM-SPRY(-)-SeV
infected Vero, CV1, LLC-MK2, 293T or MT4 cells with 5 μM of CsA for 1
h and then inoculated them with the VSV-G-pseudotyped HIV-1
vector encoding GFP. As shown in Fig. 3, CsA treatment affected HIV-1
susceptibility in opposite directions in human and OWM cells. CsA
treatment enhanced HIV-1 infection in OWM cells (Figs. 3A, C, and E)
but reduced HIV-1 infection in human cells in the presence of
functional TRIM5α (Figs. 3G and I). These results were consistent with
previous ﬁndings (Berthoux et al., 2004, 2005; Keckesova et al., 2006;
Kootstra et al., 2003; Stremlau et al., 2006; Towers et al., 2003). In the
absence of functional TRIM5α, CsA treatment also enhanced the
susceptibility of the OWM cells to HIV-1 infection (Figs. 3B, D, and F)
and diminished that of the human cells (Figs. 3H and J). These results
suggest that endogenous CypA, like exogenous CypA, can also restrict
HIV-1 in OWM cells but not in human cells.
Fig. 3. Vero (A, B), CV1 (C, D), LLC-MK2 (E, F), 293T (G, H) and MT4 (I, J) cells were
infected with SeV expressing AGM TRIM5α lacking the coiled-coil domain (A, C, E, G, I)
or CM TRIM5α lacking the SPRY domain (B, D, F, H, J) at a MOI of ﬁve PFUs per cell for
each virus and incubated at 37 °C for 16 h. Cells were treated with 5 μMof Cyclosporin A
(black circles) or vehicle control, 0.5% of dimethyl surfoxide (DMSO, white circles), for
1 h. Serially diluted VSV-pseudotyped HIV-1 vectors encoding GFP in 5 μM of
Cyclosporin A (black circles) or 0.5% of DMSO (white circles) were inoculated for 2 h.
After washing out of the inoculum, cells were cultivated for 40 h and GFP positive cells
were counted with a ﬂowcytometer. Asterisks indicate statistically signiﬁcant
differences (pb0.05, paired t-test). Representative data of at least three independent
experiments is shown.
Fig. 2. Vero (A, B), CV1 (C, D), LLC-MK2 (E, F) 293T (G, H) and MT4 (I, J) cells were
infected with SeV expressing AGM TRIM5α lacking the coiled-coil domain (A, C, E, G, I)
or CM TRIM5α lacking the SPRY domain (B, D, F, H, J) mixed with SeV expressing CypA
(black triangles), CypA-HA (crosses) or the empty SeV vector parental Z strain (white
triangles) at a MOI of ﬁve PFUs per cell for each virus and incubated at 37 °C for 16 h.
Serially diluted VSV-pseudotyped HIV-1 vectors encoding GFP were inoculated, and
infected cells were counted with a ﬂowcytometer. Asterisks indicate statistically
signiﬁcant differences (pb0.05, paired t-test). Representative data of at least three
independent experiments is shown. (K) Lysates of CV1 (lane 1), Vero (lane 2), LLC-MK2
(lane 3), 293T (lane 4) and MT4 (lane 5) cells infected with SeV expressing CypA-HA
were visualized by western blotting with an antibody against CypA. The lower and
upper bands represent endogenous CypA and exogenous CypA-HA, respectively.
516 E.E. Nakayama et al. / Virology 375 (2008) 514–520CypA binding to CA is critical for restriction by CypA in OWM cells
The hydrophobic pocket of CypA makes direct contact with HIV-1
CA proline 90 and adjacent residues on the surface-exposed h4/5 loop.
Replacement of the h4/5 loopwith SIVmac reportedly eliminates CypA
517E.E. Nakayama et al. / Virology 375 (2008) 514–520binding to CA (Bukovsky et al., 1997). In order to further elucidate the
role of CypA and CA interactions in the antiviral activity of CypA, we
investigated whether HIV-1 mutant (NL-ScaVR) or HIV-2 (GH123),
whose CAs are unable to bind CypA, are restricted to human and OWM
cells. NL-SVR, which can bind CypA and is an HIV-1 NL43 variant
carrying SIVmac vif, was used as a control virus. NL-ScaVR is a NL43
variant carrying both SIVmac vif and the SIVmac gag h4/5 loop and has
been shown to be able to grow in CM cells (Kamada et al., 2006).
Consistent with our previous ﬁnding, expression of TRIM5α lacking
the SPRY domain enhanced HIV-1(NL-SVR, NL-ScaVR) and HIV-2
infectivity in OWM cells (Figs. 4Ad, Bd, and Cd) compared with non-
interfering control (Figs. 4Ac, Bc, and Cc). Exogenous expression of
CypA suppressed the NL-SVR virus, which is able to bind CypA, in
OWM cells (Fig. 4Ad) but not in human cells (Fig. 4Ab). In contrast,
both NL-ScaVR (Fig. 4B) and GH123 (Fig. 4C), those cannot bind CypA,
were not suppressed in either human or OWM cells by exogenously
expressed CypA. Instead, those viruses tended to show slightly higher
titers in cells expressing exogenous CypA.
As for the CypA protein, it is known that H54, R55, and H126 are
crucial for the incorporation of CypA into HIV-1 virion (Dorfman et al.,
1997). When we introduced R55A substitution into an HA-tagged
version of CypA, the suppressive effect of exogeneous CypA was
eliminated in CV1 and LLC-MK2 cells (Fig. 5A), although the level of
expression in those cells was comparable to that of wild type CypA
(Fig. 5B). Expression levels of TRIM5α lacking the SPRY domain inFig. 4.MT4, 293T, Vero, LLC-MK2 and CV1 cells were infected with SeV expressing AGM TRIM
and d) mixedwith the empty SeV vector parental Z strain (white bars) or SeV expressing CypA
Cells were then superinfected with 20 ng of p24 of VSV-pseudotyped HIV-1-NL-SVR (A), HI
3 days after infection, and the level of p24 or p25 was measured wth a RETROtek antigen Emutant CypA and the wild type CypA expressing cells were also
comparable (Fig. 5B). These results indicate that CypA and CA
interaction is essential for HIV-1 restriction by CypA in OWM cells.
CypA multimerization is not required for the HIV-1 restriction in OWM
cells
In a mutagenesis study of TRIMCyp, overexpression of CypA-like
protein reportedly reduced susceptibility of cells to HIV-1 (Diaz-
Griffero et al., 2006). Javanbakht et al. (2007) reported that multi-
merization of CypA increased the anti-HIV-1 activity of CypA. Thus, it
is possible that multimerization of CypA occurs only in OWM cells but
not in human cells. To determine the extent of multimerization of
CypA in human and OWM cells, we infected 293T and LLC-MK2 cells
with SeV expressing CypA-HA and ﬁxed the cell lysates with
glutaraldehyde. CypA-HA proteins were then immunoprecipitated
by using the anti-HA antibody. As shown in Fig. 6, most of the CypA-
HA protein was monomeric in both 293T and LLC-MK2 cells,
suggesting that the multimerization of exogenous CypA is not
required for HIV-1 restriction in OWM cells.
Discussion
In the study reported here, we investigated the role of CypA in HIV-
1 restriction of OWM cells. We demonstrated that exogenous5α lacking the coiled-coil domain (a and c) or CM TRIM5α lacking the SPRY domain (b
(black bars), at a MOI of ﬁve PFUs per cell for each virus and incubated at 37 °C for 16 h.
V-1-NL-ScaVR (B) or p25 of HIV-2 GH123 (C). The culture supernatants were collected
LISA kit. Data points show means of triplicate samples with SD.
Fig. 6. Lysates of CV1 (lanes 1 and 3) and 293T (lanes 2 and 4) cells infected with SeV
expressing CypA-HAwere ﬁrst ﬁxed with 2.5 mM glutaraldehyde and then subjected to
immunoprecipitation with an anti-HA High Afﬁnity rat monoclonal antibody. CypA-HA
proteins were visualized bywestern blottingwith an antibody against HA. Ig hc and Ig lc
indicate the IgG heavy chain and light chain used for immunoprecipitation, respectively.
Fig. 5. (A) CV1 and LLC-MK2 cells were infectedwith SeV expressing CM TRIM5α lacking
the SPRY(-) domain mixed with SeV expressing CypA (black triangles), CypA-HA
(crosses), R55A-CypA-HA (white circles) or the empty SeV vector parental Z strain
(white triangles) at a MOI of ﬁve PFUs per cell for each virus and incubated at 37 °C for
16 h. Serially diluted VSV-pseudotyped HIV-1 vectors encoding GFP were inoculated,
and infected cells were counted with a ﬂowcytometer. Representative data of at least
three independent experiments is shown. (B) Lysates of CV1 (lanes 1 and 2) and LLC-
MK2 (lanes 3 and 4) cells infected with SeV expressing CM TRIM5α lacking the SPRY(-)
domain mixed with SeV expressing CypA-HA (lanes 1 and 3) or R55A-CypA-HA (lanes 2
and 4) were visualized by western blotting with an antibody against HA. Representative
data of two independent experiments is shown.
518 E.E. Nakayama et al. / Virology 375 (2008) 514–520expression of CypA suppresses HIV-1 infection in OWM cells in the
absence of functional TRIM5α and that the inhibitory activity of CypA
depends upon the interaction of CypA moiety with HIV-1 capsid. In
addition, disruption of CypA and capsid interaction by CsA treatment
enhanced the HIV-1 susceptibility of OWM cells even in the absence of
functional TRIM5α. These results suggest the presence in OWM cells of
TRIM5α-independent anti-HIV-1 activity mediated by CypA.
Knock-down of TRIM5 alone or dominant negative suppression of
functional TRIM5α caused enhancement of HIV-1 infection and
exogenous expression of CypA partially compensating for the absence
of TRIM5α in HIV-1 infection, even though the expression levels of
exogenous CypA were overwhelmingly higher than those of TRIM5α.
This result suggests that TRIM5α may play a pivotal role in HIV-1
restriction in the OWM cells used in our study. We speculate that the
mechanisms of anti-HIV-1 activity mediated by TRIM5α-independent
CypA is static, for example, by trapping the virion core in cytoplasm
and interfering with the nuclear transport of reverse transcription
complex. Although CypA itself is not strong enough to eliminate HIV-1
infection, endogenous TRIM5α can attack HIV-1 more effectively if
CypA traps virion in cytoplasm and reinforces restriction process.
Recently, two groups reported that the simultaneous knock-down
of both CypA and TRIM5 in OWM cells caused minimal additional
increase of HIV-1 infection compared with knock-down of TRIM5
alone, suggesting that CypA inhibits HIV-1 replication in OWM cells in
a TRIM5-dependent manner. They suggested that CypA is required for
CA recognition by TRIM5α. We agree that both CypA and TRIM5α are
able to suppress HIV-1 infection in OWM cells, since the most potent
suppression of HIV-1 infection in our study was observed in the
presence of both CypA and TRIM5α. However, our ﬁndings also
indicate the presence in OWM cells of TRIM5α-independent anti-HIV-
1 activitymediated by CypA. At present, the reason for the discrepancy
between their results and ours is not clear. It is possible that the
dominant negative protein we used interfered more effectively withTRIM5α function than did the RNAi used in the other studies. In this
respect, it is noteworthy that one of the two groups did observe
slightly higher HIV-1 infection after simultaneous knock-down of
CypA and TRIM5 than after knock-down of TRIM5 alone (Berthoux et
al., 2005).
The effect of CypA on HIV-1 infection in human cells is opposite to
the effect that in cells from OWM. It has been proposed that
interaction of CypA with CA protects HIV-1 against restriction by
human TRIM5α or other unknown antiviral factors (Luban, 2007;
Towers, 2007). Our ﬁndings did not support this hypothesis that CypA
protects HIV-1 from human TRIM5α, since we found that CsA
treatment of human cells suppressed the HIV-1 infection even in the
absence of functional human TRIM5α. In case of a virus unable to bind
CypA, overexpression of CypA led to slightly higher virus replication in
both human and OWMcells, although the enhancement varied among
cells. It has also been reported that CypA augmented cell proliferation
and gene expression in cancer cells (Li et al., 2005; Yang et al., 2005). It
is possible that CypA itself affects the cell signaling or innate immune
pathway to support high virus replication in both human and OWM
cells. In the case of HIV-1, which is able to bind CypA, however,
overexpression of CypA showed suppression of HIV-1 replication only
in OWM cells. This suggests that the HIV-1 restricting activity of
exogenously expressed CypA surpasses the HIV-1 enhancing effect of
CypA in OWM cells. The effect of CsA treatment was more prominent
in the presence of TRIM5α than in the absence of TRIM5α. It is
therefore likely that CsA treatment in the presence of TRIM5α
disrupted both the TRIM5α-dependent and -independent effects of
CypA, whereas CsA treatment in the absence of TRIM5α disrupted only
the TRIM5α-independent effect.
The amino acids sequence of human CypA is identical to the
sequences of OWM CypAs. The cell type speciﬁc difference in the
effect of exogenous CypA expression must thus be caused by the
difference in cellular factor(s) interacting with CypA. Diaz-Grifffero et
al. (2007) showed exogenous expression of CypA suppressed HIV-1 in
feline CRFK cells. On the other hand, Javanbakht et al. (2007) reported
that multimerized CypA but not monomeric CypA suppressed HIV-1
in canine Cf2Th cells. These ﬁndings also suggest that the effect of
exogenously expressed monomeric CypA on HIV-1 infection varies
widely among cells or species. It is further possible that a certain
OWM-speciﬁc restriction factor binds to CypA in OWM cells and thus
519E.E. Nakayama et al. / Virology 375 (2008) 514–520inhibits HIV-1 infection. The identiﬁcation of factor(s) reacting with
CypA in OWM cells is therefore important to gain an understanding of
the precise mechanisms of OWM resistance against HIV-1 as well as
the physiological function of CypA.
Materials and methods
Cloning and expression of CypA
CypA cDNA was ampliﬁed by RT-PCR from the human T cell line
MT4 by using 5′-GCGGCCGCAGCCATGGTCAACCCC-3′ as the forward
primer and 5′-ACGGCGGTCTTTTCATTCGAGTTGTCC-3′ as the reverse
primer. The ampliﬁed product was then cloned into pCR-2.1TOPO
(Invitrogen, Carlsbad, CA) and veriﬁed for nucleotide sequence
authenticity. The resultant cDNA clone served as a template for
mutagenesis to generate a hemagglutinin (HA;YPYDVPDYAA) tagged
version and an active site mutant which replaced the 55th arginine
residuewith alanine. Those cDNA fragments were then cloned into the
pSeV18+b(+) vector, and recombinant SeV carrying CypA, CypA-HA
tag, and R55A-CypA-HA were recovered with a slightly modiﬁed
previously described method (Nakatsu et al., 2006; Nakayama et al.,
2004; Takeda et al., 2005). Generation of SeV expressing CM-TRIM5α
lacking the SPRY domain (CM-SPRY(-)-SeV) (Song et al., 2007) and SeV
expressing AGM-TRIM5α lacking the coiled-coil domain (AGM-CC(-)-
SeV) were described previously (Maegawa et al submitted).
RNA interference
Si-TRIM5 was a mixture of ﬁve siRNA targeting TRIM5: si-TRIM5-1
(5′-CUGAGAAUAUACAGCCUAAdTdT-3′), si-TRIM5-2 (5′-CGGCA-
GAUUUUGAGCAACUdTdT-3′), si-TRIM5-3 (5′-GCAAUGAGCUGCA-
GAACCUdTdT-3′), si-TRIM5-4 (5′-GGUUAUAGGGUUACAGGAAdTdT-
3′) and si-TRIM5-5 (5′-GUUACAGGAAGGAGAUAAAdTdT-3′). All siRNAs
were directed against AGM TRIM5 coding sequences. The 5′ ends of
siTRIM5-1, -2, -3, -4, and -5 were located at positions 194, 551, 596,
1266, and 1275, respectively, of the TRIM5 open reading frame. For
negative control, “SiCONTROL Non-targeting siRNA#2 (Si-Cont.)” (5′-
UAAGGCUAUGAAGAGAUACUU-3′) was used (Dharmacon, Lafayette,
CO). 0×105 CV1 cells in 6-well plates were transfected with 60 pmol of
siRNA using credia-TF (Credia Japan, Kyoto, Japan) according to the
manufacturer's instructions.
Real time PCR
Total RNA extracted from siRNA transfected CV1 cells were
examined for the expression of TRIM5α using the TaqMan PCR
method according to the manufacturer's instructions (Applied
Biosystems). Sequences of the probe and primers used to speciﬁcally
detect TRIM5α were as follows. forward primer: 5′-AACCTGGAGAAG-
GAGGAAGAAGA-3′, reverse primer: 5′-CTGGGTCTGCTGCACCAT-3′
and probe: 5′-FAM-TCCGTTTCAGACTTCG-TAMRA-3′. These primers
amplify the coiled-coil region of TRIM5 gene.
Viruses and HIV-1 lentivirus vector
VSV-G-pseudo typed HIV-1-NL-SVR, HIV-1-NL-ScaVR, or HIV-2-
GH123 was prepared by transfection of 293T cells with a combination
of pMD.G (Miyoshi et al., 1998, 1997) and pNL-SVR (Kamada et al.,
2006), pNL-ScaVR (Kamada et al., 2006) or pGH123 (Shibata et al.,
1990), respectively. pNL-SVR and pNL-ScaVR were generated by PCR-
based mutagenesis by using pNL432 (Adachi et al., 1986) as a template
as reported by Kamada et al. (2006). HIV-1 vector expressing GFP was
prepared as described previously (Miyoshi et al., 1998,1997). Two days
after transfection, culture supernatants of 293T cells were collected
and assayed for their p24 or p25 level by using a RETROtek antigen
ELISA kit (ZeptoMetrix Corp., Buffalo, NY).Viral infection
Assays for the HIV-1 vector expressing GFP were performed in 24-
well plates containing 4×104 Vero, CV1, LLC-MK2, MT4 or 293T cells.
Target cells were infected with AGM-CC(-)-SeV or CM-SPRY(-)-SeV
mixed with SeV expressing CypA, CypA-HA or the empty SeV vector
parental Z strain at a multiplicity of infection of ﬁve plaque forming
units per cell for each virus and incubated at 37 °C for 16 h. Serially
diluted VSV-pseudotyped HIV-1 vectors encoding GFP were then
inoculated, and infected cells were counted with a ﬂowcytometer
(FACScan, Becton Dickinson Biosciences, San Jose, CA) 40 h after
infection.
4×104 Vero, CV1, LLC-MK2, MT4 or 293T was infected with AGM-
CC(-)-SeV or CM-SPRY(-)-SeV mixed with SeV expressing CypA or the
empty SeV vector parental Z strain at a multiplicity of infection of ﬁve
PFUs per cell for each virus and incubated at 37 °C for 16 h. Cells were
then superinfected with 20 ng of p24 of HIV-1-NL-SVR, HIV-1-NL-
ScaVR or p25 of HIV-2 GH123. The culture supernatants were collected
3 days after infection, and the level of p24 or p25 was measured with
the aid of a RETROtek antigen ELISA kit.
Immunoprecipitation and western blot analysis
We analyzed the expression levels of CypA in Vero, CV1, LLC-MK2,
293Tor MT4 cells infected with recombinant SeV expressing CypA-HA
by western blot analysis by using anti-CypA polyclonal antibody
(Afﬁnity BioReagents, Golden, CO). For analysis of the oligomeric
CypA, cell lysates were ﬁrst ﬁxed with 2.5 mM glutaraldehyde and
then precipitated with anti-HA High Afﬁnity rat monoclonal antibody
(Roche Diagnostics, Indianapolis, IN) as described previously (Mische
et al., 2005). Materials were subjected to SDS-PAGE on a 4-12%
NuPAGE Bis-Tris gel (Invitrogen) and proteins in the gel were then
electronically transferred to a PVDFmembrane (Immobilon; Millipore,
Billerica, MA). Blots were blocked and probed with anti-HA antibody
overnight at 4 °C, and then incubated with peroxidase-conjugated
anti-rat IgG (American Qualex, San Clemente, CA) and developed
using the Chemilumi-one L HRP chemiluminescent kit (Nacali, Kyoto,
Japan). Visualized images were recorded by with LAS1000 (Fujiﬁlm,
Tokyo, Japan).
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